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Background: As many as 30 million Americans at intermediate risk might benefit from screening for coronary artery disease (CAD). Recent clinical 
trials have increased the proportion of patients who are indicated for statin therapy. We aimed to characterize the pool of subjects at intermediate 
risk who do not meet guideline or trial based indications for statin therapy.
Methods: We estimated the 10-year cardiac risk in the 1999-2004 National Health and Nutrition Examination Survey (NHANES) based on the 
Adult Treatment Panel III risk model. In the intermediate risk category (10-20%), we sequentially identified persons with known cardiovascular 
disease, CAD symptoms suggesting need for diagnostic evaluation, diabetes, JUPITER trial inclusion criteria, peripheral arterial disease and those 
reporting statin use. The remaining persons were categorized by LDL levels.
Results: Of the estimated 26.6 million Americans classified as intermediate risk, 3.4 million (95% CI 2.1-4.6 million) do not meet criteria for statin 
therapy and have LDL <160 mg/dl. In this cohort, observed cardiovascular mortality was 1.2% (95% CI 0.0-3.2%) per 10 person-years of follow-up.
Conclusions: Only a small proportion of intermediate risk Americans do not meet have guideline or clinical trial indications for statin therapy. 
Cardiovascular mortality among this group is very low. These findings may have implications for designing clinical trials aimed at assessing the 
effectiveness of imaging for primary CAD screening.
 
